Shilpa Medicare Limited has uploaded the audio recording of its earnings conference call for the first quarter of FY27, providing investors with direct access to management commentary on recent financial performance. The call was held on August 5, 2026, at 16:00 hrs, following a regulatory intimation dated July 29, 2025. This disclosure ensures transparency and allows stakeholders to review the detailed discussion regarding the company's operational and financial updates for the period.

The recording is hosted on the company’s official website under the investor presentation section. Investors and analysts can access the file via the provided web link to listen to the full session, which includes questions from participants and responses from company executives. This step completes the post-earnings communication protocol required by stock exchanges.

Regulatory Compliance

The upload was confirmed in a letter addressed to the Corporate Relationship Departments of BSE Limited and the National Stock Exchange of India Limited. The communication was signed by Ritu Tiwary, Company Secretary & Compliance Officer, on August 5, 2026. The filing references the scrip code BSE - 530549 and the NSE stock symbol SHILPAMED.

This procedural update ensures that all market participants have equal access to the information discussed during the earnings call, adhering to fair disclosure norms mandated by Indian securities regulations.

Shilpa Medicare is gearing up for a pivotal fiscal year, with several key operational and regulatory milestones targeted across FY27. The company's Managing Director has expressed confidence in delivering stronger results for FY27, underpinned by a series of strategic developments spanning European market entry, oncology infrastructure expansion, and a high-profile drug master file filing.

European Commercial Supplies: A Key Revenue Milestone

Shilpa Medicare's commercial supplies to a European customer are set to commence in the second half of FY27, representing a significant upcoming revenue milestone for the company. This development signals the company's growing footprint in regulated international markets and marks a tangible step in its global commercialisation strategy.

Onco Block Expansion on Track for FY27 Completion

The company's Onco Block expansion is currently in progress, with completion expected by the end of FY27. Once finalised, the expanded facility is anticipated to enable new product launches, strengthening Shilpa Medicare's oncology portfolio. The following table summarises the key upcoming milestones:

Semaglutide DMF Filing Targeted for 1HFY27

Shilpa Medicare has outlined plans to complete its Semaglutide Drug Master File (DMF) filing by the first half of FY27. Semaglutide, a molecule with significant global demand, represents a strategic addition to the company's active pharmaceutical ingredient pipeline. The timely completion of the DMF filing would position Shilpa Medicare to participate in the growing market for this compound.

Management Confidence in FY27 Performance

The company's Managing Director has expressed confidence in achieving stronger results for FY27, reflecting optimism around the convergence of these operational milestones. The combination of new international revenue streams, expanded manufacturing capacity in oncology, and progress on key regulatory filings collectively underscores the company's strategic direction for the fiscal year ahead.